7-(trifluoromethyl)-1,2,3,4-tetrahydro-1,5-naphthyridine | 1211525-01-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-(trifluoromethyl)-1,2,3,4-tetrahydro-1,5-naphthyridine
• CAS: 1211525-01-7
• 化学式: C₉H₉F₃N₂
• 分子量: 202.179
• InChiKey: HHPPBMRYOABBPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-(trifluoromethyl)-1,2,3,4-tetrahydro-1,5-naphthyridine 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以82%的产率得到6-bromo-7-(trifluoromethyl)-1,2,3,4-tetrahydro-1,5-naphthyridine
  参考文献：
  名称：

  IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS

  摘要：

  本公开涉及杂环化合物和方法，这些方法可能作为转录激活蛋白（如CBP和P300）的抑制剂，用于治疗或预防增殖性疾病、炎症性疾病、自身免疫疾病和纤维化疾病。

  公开号：

  US20190298729A1
• 作为产物：
  描述：

  (E)-ethyl 3-(3-nitro-5-(trifluoromethyl)pyridin-2-yl)acrylate 在 dimethyl sulfide borane 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 60.0~80.0 ℃ 、101.33 kPa 条件下， 反应 8.03h， 生成 7-(trifluoromethyl)-1,2,3,4-tetrahydro-1,5-naphthyridine
  参考文献：
  名称：

  IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS

  摘要：

  本公开涉及杂环化合物和方法，这些方法可能作为转录激活蛋白（如CBP和P300）的抑制剂，用于治疗或预防增殖性疾病、炎症性疾病、自身免疫疾病和纤维化疾病。

  公开号：

  US20190298729A1

文献信息

• [EN] PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST<br/>[FR] PROCEDE D'ELABORATION D'ANTAGONISTE VIS-A-VIS DU CCR-2
  申请人：MERCK & CO INC

  公开号：WO2005044795A1

  公开（公告）日：2005-05-19

  The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3- [3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl} cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro- 2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro- 4H-pyran-4-one; (1S,4S)-4-(2,5-dimethyl-1H-pyrrol- 1-yl)-1-isopropylcyclopent-2- ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1, 6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)- 4-isopropyl-4-[3-(trifluoromethyl)- 7,8-dihydro-1,6-naphthyridin-6(5H)-yl] carbonyl}cyclopent-2-e n-1-yl)- 3-methoxytetrahydro-2H- pyran-4-amine. The invention additionally resides in the superior properties of the succinate salt of ((1R,3S)-3-isopropyl- 3-[3-(trifluoromethyl)-7, 8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl} cyclopentyl)[(3S,4S)-3- methoxytetrahydro-2H-pyran-4-yl]amine.

  本发明提供了一种高效的合成方法，用于制备((1R,3S)-3-异丙基-3- [3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺及其琥珀酸盐。本发明还提供了一种高效的合成方法，用于制备中间体(3R)-3-甲氧基四氢-4H-吡喃-4-酮；(1S,4S)-4-(2,5-二甲基-1H-吡咯-1-基)-1-异丙基环戊-2-烯-1-羧酸；以及3-(三氟甲基)-5,6,7,8-四氢-1,6-萘啶；以及用于制备前体(3S,4S)-N-((1S,4S)-4-异丙基-4-[3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊-2-烯-1-基)-3-甲氧基四氢-2H-吡喃-4-胺。该发明还在于((1R,3S)-3-异丙基-3-[3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺的琥珀酸盐的优越性能。
• IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
  申请人：Board of Regents, The University of Texas System

  公开号：US20190298729A1

  公开（公告）日：2019-10-03

  The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.

  本公开涉及杂环化合物和方法，这些方法可能作为转录激活蛋白（如CBP和P300）的抑制剂，用于治疗或预防增殖性疾病、炎症性疾病、自身免疫疾病和纤维化疾病。
• Process for the preparation of ccr-2 antagonists
  申请人：Cai Dongwei

  公开号：US20070135475A1

  公开（公告）日：2007-06-14

  The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro-4H-pyran-4-one; (1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)-4-isopropyl-4-[3-(tri-fluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopent-2-en-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine. The invention additionally resides in the superior properties of the succinate salt of ((1R,3S)-3-isopropyl-3-1[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine.

  本发明提供了一种高效合成方法，用于制备((1R,3S)-3-异丙基-3-[3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺及其琥珀酸盐。本发明还提供了一种高效的合成方法，用于制备中间体(3R)-3-甲氧基四氢-4H-吡喃-4-酮；(1S,4S)-4-(2,5-二甲基-1H-吡咯-1-基)-1-异丙基环戊-2-烯-1-羧酸；以及3-(三氟甲基)-5,6,7,8-四氢-1,6-萘啶；以及用于制备前体(3S,4S)-N-((1S,4S)-4-异丙基-4-[3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊-2-烯-1-基)-3-甲氧基四氢-2H-吡喃-4-胺。本发明还在于((1R,3S)-3-异丙基-3-1[3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺的琥珀酸盐具有优越的性能。
• Imidazopiperazinone inhibitors of transcription activating proteins
  申请人：Board of Regents, The University of Texas System

  公开号：US10899769B2

  公开（公告）日：2021-01-26

  The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.

  本公开涉及杂环化合物和方法，它们可用作转录激活蛋白（如 CBP 和 P300）的抑制剂，用于治疗或预防疾病，如增殖性疾病、炎症性疾病、自身免疫性疾病和纤维化疾病。
• Imidazopiperazine inhibitors of transcription activating proteins
  申请人：Board of Regents, The University of Texas System

  公开号：US11058688B2

  公开（公告）日：2021-07-13

  The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.

  本公开涉及杂环化合物和方法，它们可用作转录激活蛋白（如 CBP 和 P300）的抑制剂，用于治疗或预防疾病，如增殖性疾病、炎症性疾病、自身免疫性疾病和纤维化疾病。